Is Tirzepatide Safe? FDA Approvals, Side Effects and Warnings (2026)

"Is tirzepatide safe?" is the right question to ask before any prescription, and the honest answer has two parts. Tirzepatide is FDA-approved for several uses, yet it also carries real warnings that a licensed provider weighs against your health history. Here is what the label and the trials say.

Key takeaways

• Tirzepatide is FDA-approved as Mounjaro® (type 2 diabetes, first approved 2022) and Zepbound® (chronic weight management, 2023; obstructive sleep apnea with obesity, 2024).
• In the Zepbound® trials, nausea was the most common side effect, reported by 25% to 29% of adults versus 8% on placebo.
• Tirzepatide shares the GLP-1 class warnings, including a boxed warning on thyroid C-cell tumors.
• Compounded tirzepatide is not FDA-approved; the FDA determined the tirzepatide shortage resolved in December 2024.
• Severe abdominal pain, allergic reactions, vision changes or suicidal thoughts need same-day care; call 911 in an emergency.

Is tirzepatide safe? What FDA approval means

Tirzepatide is a once-weekly injection that activates two gut-hormone receptors, GIP and GLP-1, which slow stomach emptying and signal fullness. The FDA approved it as Mounjaro® for type 2 diabetes in 2022, then as Zepbound® for chronic weight management in November 2023 and for moderate-to-severe obstructive sleep apnea in adults with obesity in December 2024. The Mounjaro® label now also includes reducing the risk of major cardiovascular events in adults with type 2 diabetes who are at high risk. Brand names are trademarks of their respective owners; Forever Health Rx is not affiliated with them.

Each approval means the FDA concluded that, for the labeled use and population, the benefits outweigh the known risks. That is a population-level judgment, not a promise for any one person; individual results vary.

What "safe" means for a prescription medication

In practice, "safe" means the risks are known, manageable for a given person, and watched by someone qualified. That is why a licensed provider reviews your history and medications before deciding whether tirzepatide is appropriate for you. Submitting an online visit does not guarantee a prescription; the candidacy guide explains that review.

Common tirzepatide side effects

The Zepbound® prescribing information reports these adverse reactions in adults from 2 placebo-controlled weight-management trials, at rates above placebo. Ranges span the 3 maintenance dose levels studied. These are trial frequencies, not predictions.

In SURMOUNT-1, most digestive events were mild to moderate and occurred mainly while the dose was being increased, which the provider does gradually; the label notes they decreased over time. The pillar on semaglutide side effects covers practical ways to manage them.

Tirzepatide fatigue

Fatigue (including weakness and low energy) was reported by 5% to 7% of adults on Zepbound® versus 3% on placebo. Raise persistent tiredness with your provider, who may check for causes such as dehydration or low blood sugar.

Serious warnings on the Zepbound® label

Tirzepatide carries warnings very similar to those for semaglutide; read the full Important Safety Information before your online visit.

• Thyroid C-cell tumors (boxed warning). Seen in rats; unknown in humans. Report a neck lump, hoarseness, trouble swallowing or shortness of breath.
• Severe gastrointestinal side effects. Digestive side effects can sometimes be severe, and Zepbound® is not recommended for people with severe gastroparesis.
• Acute kidney injury. Dehydration from vomiting or diarrhea can injure the kidneys.
• Acute gallbladder disease. Upper stomach pain, fever or yellowing skin warrant a call.
• Acute pancreatitis. Severe, persistent abdominal pain that may spread to the back needs same-day evaluation.
• Hypersensitivity reactions. Anaphylaxis and angioedema have been reported.
• Hypoglycemia. Risk rises when combined with insulin or a sulfonylurea.
• Diabetic retinopathy complications. Rapid blood-sugar improvement has been linked to temporary worsening in people with type 2 diabetes.
• Pulmonary aspiration and ileus. Rare aspiration during general anesthesia or deep sedation, and ileus, have been reported. Tell every surgeon, anesthesiologist and dentist that you take tirzepatide.

In January 2026, the FDA said its evaluation did not identify an increased risk of suicidal thoughts or behavior with GLP-1 medications, including tirzepatide, and asked for that warning to be removed from the label. It still advises telling your health care professional about new or worsening depression, suicidal thoughts or unusual changes in mood.

Who should not take tirzepatide

According to the Zepbound® label, tirzepatide is contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC), with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or with a known serious hypersensitivity to it.

Providers also weigh a history of pancreatitis, severe gastroparesis, diabetic retinopathy, kidney disease or depression. The label advises stopping tirzepatide when a pregnancy is recognized, and it should not be combined with another GLP-1 medication.

Drug interactions to tell your provider about

Two label interactions matter. First, tirzepatide can reduce how well oral hormonal contraceptives are absorbed; the label advises switching to a non-oral method or adding a barrier method for 4 weeks after starting and after each dose increase. Second, combining it with insulin or a sulfonylurea raises the risk of low blood sugar, and those medications may need adjustment.

Because tirzepatide slows stomach emptying, it may also change how quickly other oral medications are absorbed, so bring a complete medication list to your online visit.

Is tirzepatide safe long term? What the trials show

In SURMOUNT-1, published in the New England Journal of Medicine in 2022, 2,539 adults with obesity or overweight but without diabetes were followed for 72 weeks. Average weight reductions ranged from about 15.0% to 20.9% across dose levels versus about 3.1% on placebo, and about 4% to 7% of participants on tirzepatide stopped because of adverse events, versus about 3% on placebo. These are study averages; individual results vary.

In SURMOUNT-4, published in JAMA in 2024, participants who stopped tirzepatide after 36 weeks regained a substantial share of the weight they had lost, while those who continued maintained their reduction on average. That is part of why it is approved for long-term use.

In type 2 diabetes, the Mounjaro® label now includes a cardiovascular risk-reduction indication for adults at high risk. Tirzepatide has a shorter post-marketing history than semaglutide, which has been approved for diabetes since 2017. See the pillar on semaglutide vs. tirzepatide for a side-by-side view.

Is compounded tirzepatide safe?

Compounded tirzepatide is not FDA-approved. The FDA does not review compounded medications for safety, effectiveness or quality, and they are not the same as the FDA-approved products Zepbound® and Mounjaro®. They are not generic versions of those products either.

The FDA determined the national tirzepatide shortage resolved on December 19, 2024, and has since clarified its policies for compounders. The agency has also warned about counterfeit and illegally marketed tirzepatide, and about adverse events that may be related to dosing errors with compounded GLP-1 injections. The guide on spotting a legitimate online GLP-1 provider lists the questions to ask.

When to seek care and how to report side effects

Call 911 for trouble breathing, swelling of the face or throat, chest pain, fainting or any thoughts of harming yourself. You can also call or text the 988 Lifeline at 988.

Contact your provider the same day for severe or persistent abdominal pain, vomiting that keeps you from holding down fluids, signs of dehydration or low blood sugar, upper stomach pain with fever or yellowing skin, a neck lump, or any change in vision.

For everyday issues, message your provider through the patient portal; clinical messages are typically answered within . You can also report to the FDA's MedWatch program at 1-800-FDA-1088 or at www.fda.gov/medwatch. To explore whether tirzepatide is an option, review the tirzepatide program, compare it in Wegovy vs. Zepbound, and start your health assessment; a licensed provider makes the final decision.